All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Clinical comparison

Teriparatide (Forteo) vs Vosoritide (Voxzogo)

An educational, source-based comparison of Teriparatide (Forteo) and Vosoritide (Voxzogo) — how each peptide works, what it's researched for, and what to know before going deeper.

Parathyroid Hormone · Anabolic Bone
Teriparatide (Forteo)

Recombinant PTH(1-34) for severe osteoporosis.

Mechanism

Recombinant fragment of parathyroid hormone (amino acids 1–34). Intermittent dosing stimulates osteoblast activity more than osteoclasts, producing net bone formation and increased bone mineral density.

Research areas
  • Postmenopausal osteoporosis
  • Male osteoporosis
  • Glucocorticoid-induced osteoporosis
Considerations
  • FDA-approved.
  • Lifetime use limited to 2 years; transient hypercalcemia possible.
Full Teriparatide (Forteo) profile →
CNP Analog · Skeletal Growth
Vosoritide (Voxzogo)

C-type natriuretic peptide analog for achondroplasia.

Mechanism

Modified C-type natriuretic peptide (CNP) analog that binds NPR-B, antagonizing overactive FGFR3 signaling in the growth plate to increase endochondral bone growth in children with achondroplasia.

Research areas
  • Achondroplasia in children ≥5 years (now ≥4 months)
Considerations
  • FDA-approved.
  • Transient blood pressure decrease; ensure adequate hydration/food before dosing.
Full Vosoritide (Voxzogo) profile →

Teriparatide (Forteo) vs Vosoritide (Voxzogo) — Key differences

  • Class: Teriparatide (Forteo) is classified as Parathyroid Hormone · Anabolic Bone, while Vosoritide (Voxzogo) is CNP Analog · Skeletal Growth.
  • Primary research focus: Teriparatide (Forteo)postmenopausal osteoporosis; Vosoritide (Voxzogo)achondroplasia in children ≥5 years (now ≥4 months).
  • Tag: FDA-Approved · Bone vs FDA-Approved · Genetic.

Related comparisons